TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

FTC challenge to Edwards JenaValve acquisition could delay FDA approval
Edwards Lifesciences asked the U.S. Federal Trade Commission (FTC) this week to dismiss the complaint against the company's acquisition of JenaValve this week. A healthcare market analysis firm also said the FTC actions will likely impact the timing of an FDA clearance of the Trilogy heart valve.
TAVR in patients with bicuspid aortic valve stenosis: Does device type matter?
More and more care teams are treating BAV stenosis with TAVR instead of surgical aortic valve replacement. Self-expanding and balloon-expandable valves appear to have their own benefits—as well as their own risks.
Hemodynamic deterioration 1 year after TAVR found in 6% of patients
Hemodynamic valve deterioration after one year was more common in patients with a small aortic annulus. In fact, receiving a larger valve was linked to a “protective” quality that appeared to help keep the risk of such complications to a minimum.
FTC challenges ‘anticompetitive’ TAVR acquisition
The FTC is working to stop Edwards Lifesciences from completing its acquisition of JenaValve. Edwards, however, is not backing down.
Exploring the value of same-day permanent pacemaker implantation after TAVR
Temporary pacemakers are typically used for at least 24 hours before care teams consider implanting a permanent device. New research out of Canada suggests it may make sense in certain scenarios to go straight to the permanent pacemaker.

TAVR, SAVR both beneficial for patients with low-gradient aortic stenosis

The new meta-analysis included data from 32 studies.

13% of TAVR patients develop acute kidney injury, increasing their risk of in-hospital mortality

Chronic kidney disease, congestive heart failure and liver disease are just some of the comorbidities associated with a greater risk of AKI.

STEMI following TAVR associated with high rates of mortality, PCI failure

The analysis, published in the Journal of the American College of Cardiology, found that post-TAVR STEMI might be rare, but it can lead to substantial complications.

Apixaban appears safe for most TAVR patients, but questions remain

Researchers tracked data from more than 1,500 patients who underwent a successful TAVR procedure from 2016 to 2019.

A milestone for Medtronic: Low-risk TAVR patients treated with Evolut ‘doing exceptionally well’ after 2 years

The two-year rates of all-cause mortality or disabling stroke were 4.3% for TAVR patients and 6.3% for SAVR patients.

Abbott’s new self-expanding TAVR system gains CE mark approval

The solution has still only been approved in the United States for investigational use.

BASILICA before TAVR is safe and effective, new data confirms

Researchers found that the procedure was associated with a high success rate and low mortality and stroke rates after 30 days.

AI model helps clinicians predict post-TAVR infective endocarditis

To build and validate their advanced AI model, researchers explored data from nearly 78,000 TAVR hospitalizations.

TAVR

FTC challenge to Edwards JenaValve acquisition could delay FDA approval

TAVR in patients with bicuspid aortic valve stenosis: Does device type matter?

Hemodynamic deterioration 1 year after TAVR found in 6% of patients

FTC challenges ‘anticompetitive’ TAVR acquisition

Exploring the value of same-day permanent pacemaker implantation after TAVR